Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZGGFY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-HER2 mAb-Compound 75
|
|||||
| Synonyms |
Anti HER2 mAb Compound 75
Click to Show/Hide
|
|||||
| Organization |
Rongchang Pharmaceuticals Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Antibody Name |
Anti-HER2 mAb
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Anti-HER2 mAb-Compound 75 linker
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 58.49% (Day 21) | Negative HER2 expression (HER2-) | ||
| Method Description |
The nude mice were implanted with a human cancer cell line(MDA-MB-231) and the ADCs (10 mg/kg) were administered through intraperitoneal injection when the tumor volume reached about 100 cubic millimeters. The tumor volumes were monitored every 3 days and animals were sacrificed at the end of 21 days and the tumors were dissected and weighed.
|
||||
| In Vivo Model | MDA-MB-231 CDX model | ||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
References